Practical Approach to Endoscopic Management for Bleeding Gastric Varices by Lim, Young-Suk
S40 Korean J Radiol 13(Suppl 1), Jan/Feb 2012 kjronline.org
INTRODUCTION
Gastroesophageal varices are present in approximately 
50% of patients with cirrhosis. Their presence correlates 
with the severity of liver disease; while only 40% of Child 
A patients have varices, they are present in 85% of Child 
C patients (1, 2). Variceal hemorrhage occurs at a yearly 
rate of 5-15%, and about 20% of cirrhotic patients with 
acute variceal bleeding die within 6 weeks (3-5). Although 
variceal bleeding ceases spontaneously in 40-50% of 
patients, the incidence of early rebleeding ranges between 
30% and 40% within the first 6 weeks, and about 40% of 
all rebleeding episodes occur in within the first 5 days (4, 6).
Gastric varices (GV) bleed less frequently than esophageal 
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varices and are the bleeding source in approximately 10-
30% of patients suffering from variceal hemorrhage (7). 
However, gastric variceal bleeding tends to be more severe 
with higher mortality. Additionally, a high proportion of 
patients, from 35% to 90%, rebleed after spontaneous 
hemostasis.
Although GV have long been recognized, our 
understanding of their natural history has lagged far behind 
that of esophageal varices. Recently, new endoscopic 
treatment options and interventional radiological procedures 
have broadened the therapeutic armamentarium for GV. 
This review provides an overview of the classification and 
pathophysiology of GV, which have direct consequences for 
management; an introduction to current endoscopic and 
interventional radiological management options for GV; 
and details of a practical approach to endoscopic variceal 
obturation (EVO) using N-butyl-2-cyanoacrylate.
Classification and Pathophysiology of GV
GV are heterogeneous entities in terms of the direction 
of blood flow, as well as their location and shape. GV are 
categorized into 4 types based on the relationship with 
esophageal varices, as well as by their location in the 
stomach: gastroesophageal varix (GOV) type 1, GOV type 2, 
http://dx.doi.org/10.3348/kjr.2012.13.S1.S40
pISSN 1229-6929 · eISSN 2005-8330Korean J Radiol 13(Suppl 1), Jan/Feb 2012 kjronline.org S41
Endoscopic Management of Bleeding Gastric Varices
isolated gastric varix (IGV) type 1, and IGV type 2 (Fig. 1) 
(8). GOV type 1 is the most common type, accounting for 
74% of all GV. However, the incidence of bleeding is highest 
with IGV type 1 followed by GOV type 2. These two types 
of varices are classified as fundal varices and are the most 
challenging varices to treat. 
The wall stress of the varix is ultimately what determines 
whether it ruptures or not. Wall stress is defined by the 
equation σ = p (r/w), in which σ is the wall stress, p is 
the transmural pressure (the portal pressure), r is the 
radius, and w is the wall width. Clearly, if an increase in 
the transmural pressure occurs, this can lead to both an 
enlargement of the varix (r) and a decrease in varix wall 
thickness (w) (9, 10). Thus, small increments in portal 
pressure can lead to an exponential increase in the wall 
stress (σ), precipitating rupture. This explains in part why 
GV, which are usually larger than esophageal varices, can 
rupture, despite possessing thicker walls and lower portal 
pressures than esophageal varices (11).
Overall, the most important predictor of hemorrhage is 
the size of varices, with the highest risk of first hemorrhage 
(15% per year) occurring in patients with large varices (12). 
Other predictors of hemorrhage are decompensated cirrhosis 
(Child B or C) and the endoscopic presence of red wale 
marks (12).
Management of Bleeding GV
Diagnostic endoscopy should be performed for acutely 
bleeding patients as soon as possible to determine the 
site of bleeding. Even patients with portal hypertension 
and documented varices can bleed from other sources than 
varices (13, 14). When a varix is identified and no other 
source of bleeding is evident, the varix should be regarded 
as the source of bleeding and should be treated to prevent 
rebleeding.
The optimal management of bleeding GV remains 
controversial due to a lack of large, randomized, controlled 
trials. Although endoscopic variceal band ligation is the 
undisputed gold standard therapy for bleeding esophageal 
varices, this approach has been less successful for the 
treatment of bleeding GV (15). Treatment options for GV 
include radiological intervention; transjugular intrahepatic 
portosystemic shunt (TIPS) or balloon-occluded retrograde 
transvenous obliteration (BRTO) (16) and endoscopic 
treatment; tissue adhesive injection; thrombin injection; 
sclerotherapy; or band ligation.
TIPS placement has been demonstrated to be useful in 
reducing rebleeding rates from GV despite that GV tend to 
bleed at lower portal pressures (11). However, TIPS seemed 
to be less effective for GV treatment than for esophageal 
varices (17). In another study, although TIPS insertion led 
to a successful reduction in the mean hepatoportal gradient 
(17 to 8.4 mm Hg), the actuarial rate of remaining free 
of rebleeding at 12 months was only 64%. Furthermore, 
TIPS was considered to be responsible for death in 13% of 
patients (18). In addition, TIPS is expensive and requires 
ongoing maintenance in the vast majority of patients. 
Currently, among the endoscopic therapeutic options 
for gastric variceal bleeding, the greatest evidence for 
successful treatment exists for EVO using N-butyl-2-
cyanoacrylate, which is recommended as a first-line 
endoscopic therapy (19-21). Uncontrolled data comparing 
therapies in bleeding fundal varices show that the best 
control of initial hemorrhage (90-100%) is achieved 
with EVO, TIPS, or BRTO (16). Three small single-center 
randomized, controlled trials compared EVO versus 
endoscopic sclerotherapy (22) or band ligation in bleeding 
GV (15, 23). All three trials are favorable for EVO regarding 
control of acute hemorrhage (15, 22), rebleeding (23), 
or complication rate (15). A small single-center study 
comparing EVO versus TIPS in the prevention of recurrent 
hemorrhage in patients in whom acute gastric variceal 
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Fig. 1. Classification of gastric varices. Adapted from Sarin (8).Korean J Radiol 13(Suppl 1), Jan/Feb 2012 kjronline.org S42
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hemorrhage was controlled with EVO showed similar 
rebleeding rates (24). Thus, it is possible that EVO would 
be as effective as TIPS, if not more so, particularly in 
patients with underlying encephalopathy, renal disease, or 
significantly decompensated liver disease.
Based on these data, all of the current guidelines, such 
as the American Society for Gastrointestinal Endoscopy 
guidelines, the American Association for the Study of 
Liver Diseases guidelines, and the Baveno IV Consensus, 
recommend EVO as first-line treatment for bleeding GV, 
with the option of TIPS where endoscopic therapy is not 
available (19-21). 
Practical Considerations in EVO for Bleeding GV
Because EVO has the potential risk of serious 
complications, complying with standard injection technique 
is important to reduce the risks: 1) dilution of 0.5 mL 
N-butyl-2-cyanoacrylate with 0.5 mL or 0.8 mL of Lipiodol, 
2) limiting the mixture volume to 1.0-1.3 mL per injection 
to minimize embolism risk, 3) repeating intravariceal 
injections of 1.0-1.3 mL each until hemostasis is achieved, 
4) obliteration of all tributaries of the FV, 5) repeat 
endoscopy 1-4 days after the initial treatment to confirm 
complete obliteration of all visible varices and repeat EVO if 
necessary to accomplish complete obliteration (25).
Real-time fluoroscopy monitoring is not always necessary. 
An overtube should be kept readily available to easily 
remove and re-insert the endoscope during the procedure 
and also to prevent aspiration of gastric contents into the 
patient’s airway. A specialized catheter should be used, 
and distilled water is better than normal saline because 
cyanoacrylate may coagulate in contact with saline. 
Goggles are required for eye protection of the patient and 
the clinical personnel from splashes of cyanoacrylate during 
preparation and injection of the glue. 
A routine check with dynamic CT scanning prior to EVO is 
strongly recommended (26-28). CT scanning is very helpful 
for identifying the presence and type of GV, to assess GV 
outflow direction, such as a gastro-renal shunt, to assess 
the risk of systemic embolization by EVO, to identify the 
presence of hepatocellular carcinoma with or without 
portal vein thrombosis, and to evaluate the applicability of 
salvage treatments, such as TIPS or BRTO, in cases of EVO 
failure.
In cases with active bleeding, securing the endoscopic 
view to the fundus is difficult due to the large amount of 
blood in the gastric lumen. In such cases, changing the 
position of the patient to an upright or prone position 
is sometimes dramatically helpful. In a case with a large 
fundal varix, the dome area of the varix has the highest 
pressure with a high speed of blood flow (Fig. 2). Thus, it 
is better to inject at the side of the varix first, moving the 
injection to the dome in a stepwise manner.
Potential Complications of EVO
Cyanoacrylate injection may cause some serious 
complications, including embolization into the renal 
vein, IVC, pulmonary or systemic vessels, fever, 
paravariceal injection with mucosal necrosis and bleeding, 
intraperitoneal injection inducing severe pain, needle 
sticking in the varix, and adherence of the glue to the 
endoscope. However, most of these complications can be 
prevented by keeping a standardized injection technique, 
and the overall incidence of complications is low (25, 
29). Antibiotic prophylaxis should be administered to 
all cirrhotic patients with GI bleeding, whether EVO is 
performed or not.
Summary
Early endoscopic evaluation is essential for the diagnosis 
and treatment of variceal bleeding. EVO with cyanoacrylate 
Fig. 2. Strategic approach for endoscopic variceal obturation 
for large fundal varices. Intravariceal pressure at top of variceal 
dome (arrow) is highest leading to immediate extrusion of injected 
cyanoacrylate and massive uncontrollable bleeding. Thus, it is 
safer to first inject cyanoacrylate at side area of varix (arrowheads) 
where pressure is lower.Korean J Radiol 13(Suppl 1), Jan/Feb 2012 kjronline.org S43
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glue injection is the recommendation of choice for acute GV 
bleeding, with the option of TIPS where endoscopic therapy 
is not available. By keeping a standardized technique, EVO 
can be performed safely and effectively. 
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